Circovirus

It’s one of the most devastating and economically damaging pig diseases in the world: Porcine circovirus associated disease (PCVAD). It can strike early or appear in a late form. And once it strikes, the consequences are never good.

 Circovirus

BOEHRINGER INGELHEIM INTRODUCES COMBINATION SWINE VACCINE

  • 10 minutes

US - Boehringer Ingelheim has introduced FLEXcombo 250 Doses HSB swine vaccine, a circovirus and M. hyo vaccine package featuring a larger M. hyo bottle for easier mixing.

 Circovirus

ONE BILLION PIGS VACCINATED WITH INGELVAC CIRCOFLEX®

  • 5 minutes

Veterinarians and farmers across the globe have reached the landmark of protecting one billion pigs from the potentially devastating effects of Porcine Circovirus Disease (PCVD) using Ingelvac CircoFLEX®.

 Circovirus

PCV2 RESEARCH PROJECTS AWARDED TO FRANCE & SPAIN

  • 10 minutes

For the fifth time, the European PCV2 Research Award sponsored by Boehringer Ingelheim funds research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. Nine high quality research proposals were submitted from seven different countries (UK, Italy, Spain, Sweden, Denmark, Estonia, and France).

 Circovirus

FIRST PCV-2/ M. HYO VACCINE COMBINATION REGISTERED

  • 5 minutes

The EU Commission has approved the simultaneous use of the pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® in the European Union. Boehringer Ingelheim will market this unique vaccine concept under the name FLEXcombo®.

It can be of your interest
Others

METACAM FOR PIGS NOW AVAILABLE AS ORAL SUSPENSION

  • 5 minutes

Boehringer Ingelheim’s market leading Animal Health medication Metacam® (active ingredient: Meloxicam) obtained EU wide marketing authorisation as an oral suspension in a concentration of 15 mg/ml for use in pigs.

 Circovirus

PCV2 RESEARCH PROJECTS AWARDED TO FRANCE & SPAIN

  • 10 minutes

For the fifth time, the European PCV2 Research Award sponsored by Boehringer Ingelheim funds research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. Nine high quality research proposals were submitted from seven different countries (UK, Italy, Spain, Sweden, Denmark, Estonia, and France).